NCIC Clinical Trials Group

Breast Disease Site Committee Meeting Agenda

Delta Chelsea Hotel, Toronto, Ontario
Room: Mountbatten
Saturday, April 27, 2012: 10:00 AM – 4:15 PM
Co-Chairs: T. Whelan / K. Gelmon

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
• To understand and address, through clinical and translational research, the disease burden associated with breast cancer both in the adjuvant and the metastatic setting in Canada
• To review recent developments in the understanding of molecular biology and new therapeutics as these relate to breast cancer
• To update, review, and discuss recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group
• To place the results of clinical studies in the context of ongoing care of patients in Canada with breast cancer and to translate these results into clinical practice
• To provide a learning environment supportive to new investigators

10:00am Welcome T. Whelan/K. Gelmon
10:05am Update on Reorganization of Cooperative Groups T. Whelan/K. Gelmon/L. Shepherd

10:20am Intergroup Proposals

CTEP Proposals
• ALTERNATE Trial (Clinical Stage II/III ER+ NeoAdjuvant) K. Gelmon
• SWOG 1207 (Phase III Endocrine Therapy +/- Everolimus, High Risk) K. Gelmon
• A11201 (Telephone Intervention/Weight Loss/IDFS/Obesity) P. Goodwin/R. Segal

BIG Proposals
• PARP2 Inhibitor K. Gelmon
• HER2 K. Gelmon
• TDM1 in Early Breast Cancer K. Gelmon

Other Intergroup Proposals
• Low Risk DCIS E. Rakovitch
11:30am Invited Speaker - Dr. David Huntsman, Medical Director CTAG, Director OvCaRe, Department of Pathology, BCCA

12:00 Noon Lunch

1:30pm March 28th 2013 Retreat and Proposals
- A Randomized Phase II Pre-Operative Trial Comparing 2 Different Doses of the CDK4/6 Inhibitor PF0332991 as well as PF0332991 to Letrozole in Women with Operable or Inoperable Locally Advanced ER+ Breast Cancer M.Basik
- A Pragmatic Study of de-escalated (every 12 weeks) Versus Standard (every 3-4 weeks) Bone-Targeted Agents in Women with Bone Metastases from Breast Cancer (The DeBaTe Study) M.Clemons
- Regional Radiotherapy in Women with Early Breast Cancer Treated by Breast Conserving Surgery and Sentinel Lymph Node Biopsy Alone, with Minimal Nodal Disease I.Kong/T.Berrang/V.Theberge
- A Phase II Feasibility Study of Stereotactic Body Radiotherapy (SBRT) in the Management of Oligometastatic and Oligoprogresive Breast Cancer Patients A.Sahgal/A.Swaminath
- Pathological Complete response Tailored Trastuzumab Treatment (PACT) Clinical Trial S.Verma

2:40pm Reports from Working Groups
- Working Group for Novel Targets in Breast Cancer P.Bedard
- LABC/ Neoadjuvant Working Group M.Basik

3:00pm IND Trials:
- IND.213 (Phase II Reolysin/Paclitaxel in Advanced/Metastatic) S.Ellard/V.Bernstein

3:10pm Open Trials:
- MA.33 (TROG 07.01: Non-low risk DCIS of breast) I.Olivotto
- MA.34 (BIG 4-11/APHINITY/Pertuzumab) S.Dent

3:30pm CTSU Trials:
- MAC.14 (ECOG 2108 – Local Therapy in Stage IV) M.Basik
- MAC.15 (SWOG S1007 – Responder Trial) S.Chia/B.Dhesy

3:50pm Closed Trials:
- MA.17R (Letrozole vs Placebo after AI) W.Parulekar
- MA.20 (Regional Radiation Therapy in Early Breast Cancer) T.Whelan
- MA.21 (Adjuvant Chemotherapy) M.Burnell
- MA.31 (Lapatinib vs Trastuzumab in Metastatic) W.Parulekar/K. Gelmon
- MA.32 (Metformin + NSABP Fatigue MA.32F + Alliance Breast Density) P.Goodwin

4:15 pm Closing Remarks and Adjournment